Helius Medical Technologies to Present at Upcoming Healthcare Investor Conferences in September
NEWTOWN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. HSDT (“Helius” or the “Company”), a neurotechnology company focused on neurological wellness, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at two upcoming health care conferences as follows:
|HC Wainwright 24e Annual Global Investment Conference (Virtual)|
|Appointment:||From Monday September 12, 2022 to Wednesday September 14, 2022|
|Time:||On demand, starting at 7:00 a.m. ET*|
|*For HC Wainwright Conference registrants.|
|Ladenburg Thalman 2022 health care conference (New York City)|
|Date:||Thursday, September 29, 2022|
|Time:||10:00 a.m. ET|
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotechnology medical device company focused on neurological deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promote neuroplasticity, with the aim improve the lives of people with neurological diseases. The company’s first commercial product is the Wearable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.
About PoNS Device and PoNS Therapy
The Wearable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, comprising a controller and a mouthpiece, that delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment for gait impairment due to mild to moderate symptoms of multiple sclerosis (“MS”) and should be used in conjunction with a training program. supervised therapeutic exercises in patients 22 years and older by prescription only. Helius is advancing PoNS post-approval research in MS through a recently launched Therapeutic Experience Program (TEP), designed to partner with neurologists and neurorehabilitation therapists at 10-12 U.S. Centers of Excellence, which express interest in becoming “early adopters” of PoNS therapy. For more information visit www.ponstherapy.com.
PoNS is also authorized for sale in Canada for two indications: (i) for use as a short-term (14 weeks) treatment of chronic balance deficit due to mild to moderate traumatic brain injury (“mmTBI”) and should be used in conjunction with physical therapy; and (ii) for use as a short-term (14 weeks) treatment of walking impairment due to mild and moderate symptoms of MS and should be used in conjunction with physical therapy. PoNS is also cleared for sale in Australia for short-term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.
Lisa M. Wilson, On-Site Communications, Inc.
Such. : 212-452-2793
Email: [email protected]